SurModics (SRDX) Tops Q1 EPS by 18c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/7/2026

1. USO
2. MRVL
3. SPY
4. BBIO
5. NVDA
6. GOOGL
7. OPCH
8. CHRW
9. AMD
10. HUBS

Go back to SurModics (SRDX) Tops Q1 EPS by 18c

Surmodics Reports First Quarter Fiscal 2022 Results

February 3, 2022 7:30 AM EST

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2022 first quarter ended December 31, 2021.

Summary of First Quarter and Recent Highlights

Revenue of $23.0 million, an increase of 3% year-over-year GAAP EPS of $(0.20), non-GAAP EPS of $(0.13) First commercial sale of Pounce Arterial Thrombo-embolectomy System

I am pleased with our first quarter performance. We delivered revenue growth and made critical progress on our SurVeil drug-coated balloon PMA submission... More